Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2022-04-25 M&A Activity
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Grifols acquires majority of voting rights in Biotest
M&A Activity Classification · 100% confidence The document is a press release dated April 25, 2022, announcing that Grifols has completed its takeover offer and acquired a majority of voting rights (96.2%) in Biotest AG. The key terms used are 'Takeover', 'acquisition', and 'merger'. This clearly falls under the category of corporate actions related to mergers, acquisitions, or takeover bids. Reviewing the definitions, 'M&A Activity (Code: TAR)' is defined as 'Announcements and documents related to merger proposals or takeover bids.' This is the most accurate classification.
2022-04-25 English
Biotest AG: Biotest submits marketing authorisation application for IgG Next Generation and signed first licensing agreement
Regulatory Filings Classification · 95% confidence The document is a press release dated April 7, 2022, announcing two key corporate events: the submission of a marketing authorisation application for a new product (IgG Next Generation) and the signing of a first licensing agreement for that product. It discusses regulatory affairs ('Head of Regulatory Affairs / Development Products'), clinical trials, and commercial agreements. This content does not fit neatly into standard periodic financial reports (10-K, IR, ER) or specific corporate actions like dividends or director dealings. It is a general corporate update concerning product development and commercial strategy, which is best categorized as a general Regulatory Filing (RNS) or potentially a miscellaneous corporate announcement, as it doesn't align with the specific definitions for M&A (TAR), Capital Changes (CAP/SHA), or Board changes (MANG). Given the nature of the announcement (submission to authorities and licensing deal), RNS serves as the most appropriate general regulatory/corporate news category when a more specific one is unavailable.
2022-04-07 English
Biotest Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 05.05.2022 in Dreieich mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is explicitly titled 'Einladung zur ordentlichen, virtuellen Hauptversammlung 2022' (Invitation to the Annual General Meeting 2022) and contains an 'AGM Announcements' tag. The agenda items (Tagesordnung) include voting on the annual financial statements, dividend allocation, discharge of board/supervisory members, election of the auditor, and elections to the supervisory board. Furthermore, it specifically addresses the approval of the Remuneration Report (§ 162 AktG), which is often presented at the AGM. The core purpose of this document is to convene and provide the agenda for the Annual General Meeting (Hauptversammlung). This directly corresponds to the AGM Information category.
2022-03-29 German
Biotest AG: Biotest exceeds sales guidance in fiscal year 2021
Earnings Release Classification · 100% confidence The document is titled 'Biotest exceeds sales guidance in fiscal year 2021' and contains key financial metrics (Revenue, EBIT, EBT, Loss) for the fiscal year 2021, along with an outlook for 2022. It explicitly mentions 'Annual Results' as a keyword and discusses the full year's performance. This strongly indicates it is an announcement of the annual financial results. Although it mentions the Annual Report is available online, the content provided is the summary press release of the results, which aligns best with the Earnings Release (ER) category, as it provides the initial, high-level financial summary for the period. Since it covers the full fiscal year, it is the annual equivalent of an ER, but given the options, ER is the closest fit for a results announcement summary, rather than the comprehensive 10-K. However, because it explicitly covers the *full fiscal year* and uses the term 'Annual Results', it is often classified as the primary announcement of the Annual Report's figures, which is distinct from a quarterly ER. Given the options, and the focus on the full year's performance summary, it is a strong candidate for ER, but let's re-evaluate against 10-K. A 10-K is the official SEC filing. This appears to be a press release accompanying the 10-K filing. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is the annual highlight announcement, ER is the most appropriate classification among the choices provided for this type of press release summary. FY 2021
2022-03-24 English
Remunerations Report 2021
Remuneration Information Classification · 100% confidence The document is a formal 'Remuneration Report' for Biotest AG for the financial year 2021, including an independent auditor's assurance report pursuant to Section 162 (3) AktG. This document details the compensation structure, fixed and variable remuneration components, and long-term incentive programs for the Board of Management and Supervisory Board. According to the provided filing definitions, reports detailing executive and director compensation are classified as 'DEF 14A'.
2022-03-24 English
Geschäftsbericht 2021
Annual Report Classification · 100% confidence The document is titled 'Geschäftsbericht 2021' (Annual Report 2021) for the Biotest Group. It contains a comprehensive set of financial statements (Balance Sheet, Income Statement, Cash Flow Statement), management's discussion and analysis (Konzernlagebericht), and auditor/board reports. It is a full-length annual report, not an announcement or a summary. FY 2021
2022-03-24 German

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.